Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal study seeks to evaluate the efficacy of Ivonescimab, a novel bispecific antibody, in combination with platinum-doublet chemotherapy as a second-line treatment for patients with epidermal growth factor receptor-mutated (EGFRm) non-squamous […]